Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030 : Results from a phase 1/2 clinical trial-Reference-Cited by-同舟云学术

Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030 : Results from a phase 1/2 clinical trial

Published:2021-10-26 Issue:9 Volume:49 Page:1048-1059
ISSN:1442-6404
Container-title:Clinical & Experimental Ophthalmology
language:en
Short-container-title:Clin Experiment Ophthalmol

Author:

Hwang Christopher K.¹^ORCID,Chew Emily Y.¹,Cukras Catherine A.¹,Keenan Tiarnan D. L.¹,Wong Wai T.²,Linehan W. Marston³,Chittiboina Prashant⁴,Pacak Karel⁵,Wiley Henry E.¹

Affiliation:

1. Division of Epidemiology and Clinical Applications National Eye Institute, National Institutes of Health Bethesda Maryland USA

2. Section on Neuron‐Glia Interactions in Retinal Disease National Eye Institute, National Institutes of Health Bethesda Maryland USA

3. Urologic Oncology Branch National Cancer Institute, National Institutes of Health Bethesda Maryland USA

4. Neurosurgery Unit for Pituitary and Inheritable Diseases National Institute of Neurological Disorders and Stroke, National Institutes of Health Bethesda Maryland USA

5. Section on Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health Bethesda Maryland USA

Funder

Heed Ophthalmic Foundation

National Institutes of Health

Publisher

Wiley

Subject

Ophthalmology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ceo.14001

Reference39 articles.

1. Clinical Features and Natural History of von Hippel-Lindau Disease

2. von Hippel–Lindau Disease